We found that decreased PTPN12 expression was a prognostic factor for poor cancer-specific survival and recurrence-free survival of HCC patients (P<0.001, Table 3) independent of serum AFP levels, tumor size, multiplicity, clinical stage and vascular invasion as evidenced by multivariate analysis. This evidence concerns the gene AFP and hepatocellular carcinoma.